Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6098 | SR 140333 |
| Potent NK1 receptor antagonist (Ki = 0.74 nM. IC50 = 1.6 nM). Inhibits substance P-invoked calcium mobilization and outward current (IC50 = 1.3 nM); blocks NK1-mediated nitric oxide-dependent vasodilation in vivo. | |
| BCC6101 | JNJ 5207852 dihydrochloride |
| High affinity histamine H3 receptor neutral antagonist (pKi values are 8.9 and 9.2 in rat and human respectively). Brain penetrant and orally active. Has 3- and 100-fold higher affinity than thioperamide for rat and human H3 receptors respectively. Suppresses slow-wave sleep; exhibits wake-promoting effects in rodent arousal models. | |
| BCC6102 | ES 936 |
| Mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase (NQO1). Induces growth inhibition in human pancreatic carcinoma (MIA PaCa-2) and adenocarcinoma (BxPC-3) cell lines with IC50 values of 108 and 365 nM respectively. Also inhibits TNF-α-induced E-selectin protein expression in human bone marrow endothelial cells. Exhibits no effects on other cellular reductases or levels of acid-soluble thiols. | |
| BCC6103 | ProTx II |
| Selective NaV1.7 channel blocker. Shifts activation gating positively and decreases current magnitude. Displays 100-fold selectivity over other sodium channel subtypes. | |
| BCC6104 | 5'-Fluoroindirubinoxime |
| Inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) (IC50 = 15 nM). Displays selectivity for FLT3 against 6 other kinases including EGFR. Displays antiproliferative activity against the MV4;11 cell line (expressing constitutively active FLT3) and a number of cancer cell lines, including SNU-638 (stomach carcinoma) and HT-1080 (fibrosarcoma). | |
| BCC6105 | PM 102 |
| Peptide that reverses the anticoagulant effect of heparin. Potently binds heparin (Kd = 36 nM in vitro). | |
| BCC6106 | MRE 3008F20 |
| Potent adenosine A3 receptor competitive antagonist. Selective for human A3 receptors over human A1 and A2A receptors (Ki values are 0.29, 141 and 1197 nM respectively). Potently inhibits agonist-induced cyclic AMP elevation in resting T lymphocytes (IC50 = 5 nM). | |
| BCC6107 | Flunitrazepam |
| Ligand at the GABAA receptor benzodiazepine modulatory site. Exhibits hypnotic effects; also displays anxiolytic and sedative properties. | |
